Active substance
Results for the substance onasemnogen abeparvovec
1 result
About this active substance
Onasemnogene abeparvovec is a gene therapy used for the treatment of spinal muscular atrophy (SMA) in patients with specific genetic mutations. It delivers a functional copy of the SMN1 gene, which is essential for the normal functioning of motor neurons.
The medication is administered as a single intravenous infusion, as directed by a doctor. It is important for patients to be closely monitored before and after administration to prevent potential complications.
Patients should be aware of potential side effects, such as elevated liver enzymes, vomiting, or fever. It is important to inform the doctor of any unusual symptoms.
Common side effects include elevated liver enzymes, vomiting, fever, and decreased appetite. In rare cases, severe reactions such as liver failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.
The medication is administered as a single intravenous infusion, as directed by a doctor. It is important for patients to be closely monitored before and after administration to prevent potential complications.
Patients should be aware of potential side effects, such as elevated liver enzymes, vomiting, or fever. It is important to inform the doctor of any unusual symptoms.
Common side effects include elevated liver enzymes, vomiting, fever, and decreased appetite. In rare cases, severe reactions such as liver failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.